CJC-1295 + Ipamorelin
A GHRH analog paired with a selective ghrelin-receptor agonist — the most-studied dual-pathway growth-hormone research combination.
01At a Glance
| Compound | CJC-1295 + Ipamorelin |
| Classification | Endocrine research compound |
| Constituents | CJC-1295 (no DAC) 5 mg — 3,367.8 g/mol Ipamorelin 5 mg — 711.85 g/mol |
| Molecular weight | Blend — see constituents |
| Sequence / Form | CJC-1295 (no DAC) 5 mg · Ipamorelin 5 mg |
| Purity | ≥98% HPLC, identity verified by mass spectrometry |
| Documentation | Batch-specific Certificate of Analysis available |
| Appearance | White lyophilized powder |
| Storage | Store sealed at 2–8°C. Long-term storage per certificate guidance. |
| Use | Research Use Only. Not for human or veterinary use. |
02Mechanism of Action
This blend combines two compounds that act on separate receptors within the same axis. CJC-1295 without DAC (also called Mod GRF 1-29) is a modified GHRH(1-29) analog studied for binding at the GHRH receptor on somatotroph cells.
Ipamorelin is a selective pentapeptide agonist at the growth-hormone secretagogue receptor (ghrelin receptor), noted in the literature for its selectivity — minimal reported effect on cortisol or prolactin compared with earlier secretagogues.
Because the two engage distinct receptors, research examines whether the combination produces effects on somatotroph signaling that differ from either compound alone. The combination is a common experimental pairing rather than a separately characterised entity.
Research framing only · No human-use claims
03Research Context
- Dual-pathway somatotroph signaling assays
- GHRH-receptor and GHS-receptor co-stimulation models
- Receptor-selectivity comparison studies
- Pulsatile secretion research in cell models
04Quality & Verification
Ethos Bio presents compound information with an emphasis on identity verification, purity analysis, certificate access, and storage guidance. Product-specific documentation is available through the certificate page where applicable. Cold-chain shipping is available where required, and inventory is held under refrigerated conditions at our fulfillment center with temperature-logging protocols in place.
05FAQ
What is in this blend?
A single lyophilized vial containing CJC-1295 without DAC 5 mg and Ipamorelin 5 mg — 10 mg total peptide content.
Is this CJC-1295 with or without DAC?
Without DAC — the Mod GRF (1-29) form, which has a substantially shorter reported half-life than the DAC-conjugated version. CJC-1295 DAC is sold separately.
Why combine a GHRH analog with a ghrelin-receptor agonist?
They bind different receptors on the same cell population. Research pairs them to study whether co-stimulation of the two pathways differs from stimulating either alone.
How should CJC-1295 + Ipamorelin be stored?
CJC-1295 + Ipamorelin ships lyophilized and should be handled per standard research-peptide practice — kept cold, protected from light and moisture, and reconstituted only for laboratory use. Cold-chain handling is used where required. For research use only.
Is CJC-1295 + Ipamorelin approved for human use?
No. CJC-1295 + Ipamorelin is sold strictly for laboratory research use only and is not a drug or supplement. It is not approved for human or veterinary use or consumption.
How is CJC-1295 + Ipamorelin tested at Ethos Bio?
Every lot is independently verified by Kovera Labs on a third-party analytical panel — RP-HPLC purity and HPLC-MS identity confirmation — and a lot-specific certificate of analysis issued to Ethos Bio ships with the vial. See How We Test for the full methodology.